We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




Novel Adipokine Biomarker Reported for Insulin Resistance and Atherosclerosis

By LabMedica International staff writers
Posted on 21 Jul 2021
Diabetes Mellitus is a chronic condition occurring due to inadequate production or inadequate action of insulin, ultimately leading to hyperglycemia. Prediabetes, regarded as a precursor of diabetes, is a condition with elevated plasma glucose above normal levels, but below that of clinical disease.

Atherosclerotic cardiovascular diseases contribute to the world’s largest disease burden and are a leading cause of morbidity and mortality in both diabetics and prediabetics, accounting for about two third of mortality in diabetics. Increased levels of adipose derived cytokine (adipokine) apart from having immunological role, also have role in insulin resistant states and the process of atherosclerosis.

Medical Scientists at the Dr. Ram Manohar Lohia Hospital (New Delhi, India) included in a case control study 60 prediabetic patients and 60 age, sex, BMI matched controls. In both cases and controls serum levels of fasting and postprandial blood glucose, glycated hemoglobin (HbA1c) using a Vitros dry chemistry analyzer (Ortho Clinical Diagnostics, Bridgend, UK) and fasting insulin levels were measured by Chemiluminescence Immuno Assay (CLIA) on Vitros ECiQ. Homeostatic model assessment of insulin resistance (HOMA-IR) values in both the groups was calculated using fasting glucose and insulin levels. Serum Retinol Binding Protein-4 (RBP4) levels were measured using ELISA (IMMUNDIAGNOSTIK AG, Bensheim, Germany). The values obtained were compared between cases and controls. Carotid Intima-Media Thickness (CIMT) was only measured in cases using B-mode ultrasonography.

The investigators reported that the Median (IQR) of fasting plasma insulin levels (uIU/ml) in cases was 11.3 versus that of controls which was 5.73. HOMA-IR median (IQR) in cases and controls was 3.12 and 1.21 respectively. Median (IQR) for RBP4 in cases was 67.4 which were significantly higher as compared to controls 33.92. Significant positive correlation was seen between RBP4 with both, HOMA-IR and mean CIMT with correlation coefficients of 0.3693 and 0.621 respectively. On performing univariate linear regression analysis it was found that with increase in serum RBP4 levels by 1 mg/L, HOMA-IR and mean CIMT significantly increased by 0.007 units and 0.001 mm respectively.

The authors concluded prediabetics have been found to have more risk of cardiovascular events as compared to normoglycemics. Early assessment of the same with the use of novel biomarkers like RBP4 can be considered for early detection of atherosclerosis in prediabetic individuals. The study was published in the July 2021 issue of the Journal of the Association of Physicians of India.

Related Links:
Dr. Ram Manohar Lohia Hospital
Ortho Clinical Diagnostics
IMMUNDIAGNOSTIK AG



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Piezoelectric Micropump
Disc Pump
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.